UNSPSC 51101903: Primaquine

This classification denotes an antimalarial agent with the molecular formula C15H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MVR3634GX1, chemically known as 1,4-pentanediamine, n4-(6-methoxy-8-quinolinyl)- (9ci) but generally known as primaquine, which bears US NIH Compound Identifier 4908. European Medicines Agency schedules Primaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10043MIG. The term PRIMAQUINE is an International Non-Proprietary Name.

UNSPSC 51101903 Primaquine, a Commodity code, does not reflect the work actually being solicited under this category in recent state and local opportunities. The code nominally covers a specific antimalarial pharmaceutical, but the recent opportunities tagged to it span naloxone procurement, direct-to-manufacturer pharmacy programs, emergency medical supplies for fire departments, and generic multi-source pharmaceuticals through cooperative purchasing — none of which involve primaquine. The mismatch between the code's nominal scope and the actual solicitations suggests either tagging error or substantial scope drift in how this code is being used at the state and local level.

Recent activity under this code appears across state health agencies and county health systems, with issuing bodies including Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa; and the Minnesota Multistate Cooperative Purchasing Alliance serving multiple states. Geographic spread includes Florida, Texas, and Minnesota, with multi-state participation through MMCAP. Representative solicitations include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, due July 26, 2023); the City of Tampa's IFB for emergency medical and first aid supplies for the Fire Department Rescue Division (169 line items, estimated contract value $700,000.00, due March 13, 2026, with 5% bid discount for certified Small Local Business Enterprises); Texas HHS's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers (proposals due March 26, 2026, effective July 1, 2026). The code shows active procurement but limited relevance to the primaquine commodity designation itself.